spacer
home > pmps > winter 2001 > preventive medicine - why the pharmaceutical industry needs to invest in prevention and cure to ensure effective brande protection
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Preventive Medicine - Why the Pharmaceutical Industry Needs to Invest in Prevention and Cure to Ensure Effective Brande Protection

Historically, pharmaceutical companies have tended to adopt a pragmatically conservative approach to problems of brand infringement and counterfeiting. Whilst they are ready to act whenever threats to public safety arise, they are understandably reluctant to publicise such incidents for fear of adverse effects on consumer confidence and share prices. However, a reactive approach to brand protection is becoming increasingly untenable - the changing value and role of pharmaceutical brands and the globalisation of the market present issues that demand a more comprehensive protection strategy.

New Market Trends - New Risks

A number of emerging trends in the pharmaceutical industry have serious implications for manufacturers and the ways in which they protect themselves, their products and, ultimately, their profits.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Keith Widdowson of De La Rue Brand Protection - Pharmaceuticals
Keith Widdowson has worked in the pharmaceutical industry for nearly 20 years, in some of the largest pharma companies such as AstraZeneca and Novartis. He has recently been responsible for ensuring that major brands are truly global and he has applied key branding elements to all commercial and manufacturing components.

spacer
Keith Widdowson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Ypsomed and Dexcom enter into partnership to drive closed loop system

Burgdorf/San Diego – Ypsomed (SWX:YPSN) and DexCom Inc. (NASDAQ:DXCM), the world's leading provider of continuous glucose monitoring (CGM) systems, announce their partnership to drive development of a hybrid closed loop system. The partnership is an important milestone in the further development of individualised diabetes therapy. In a first step, CGM data from Dexcom will be integrated into the mylife™ App from Ypsomed.
More info >>

White Papers

Advanced BioDesign Outlines Solutions

Advanced BioDesign

Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, clients may develop and produce antibodies according to customers' specific needs. The company offers: real support and advice from a dedicated team all along your project; large and modern SPF animal facility; ethical treatment of animals. The evaluation of a project is free-of-charge and with no obligation. Dedicated project managers will work with clients from the beginning to the end of a custom antibody project to ensure the highest level of quality and service.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement